L
Livia Pica-Mattoccia
Researcher at National Research Council
Publications - 44
Citations - 2509
Livia Pica-Mattoccia is an academic researcher from National Research Council. The author has contributed to research in topics: Schistosoma mansoni & Hycanthone. The author has an hindex of 23, co-authored 44 publications receiving 2311 citations. Previous affiliations of Livia Pica-Mattoccia include Rensselaer Polytechnic Institute.
Papers
More filters
Journal ArticleDOI
Schistosomiasis control: praziquantel forever?
TL;DR: Praziquantel is currently the only available antischistosomal drug and it is distributed mainly through mass administration programs to millions of people every year, with major flaw is its lack of efficacy against the immature stages of the parasite.
Journal ArticleDOI
Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment.
TL;DR: Early worm contraction was observed in all cases, even after exposure to sub-lethal concentrations of praziquantel or upon exposure of the largely refractory 28-day-old schistosomes, although in these instances, worms resumed movements and normal shape upon drug removal and were able to survive.
Journal ArticleDOI
Antischistosomal drugs: Past, present … and future?
TL;DR: The reported occurrence of drug-resistant schistosomes after treatment with oxamniquine and praziquantel suggests strict monitoring of such phenomena and encourages renewed efforts toward the development of multiple drugs against this human parasite.
Journal ArticleDOI
Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs.
Michael J. Doenhoff,Paul Hagan,Donato Cioli,V. Southgate,Livia Pica-Mattoccia,Sanaa S. Botros,Gerald C. Coles,L.A. Tchuem Tchuenté,A. Mbaye,Dirk Engels +9 more
TL;DR: Treatment with praziquantel (PZQ) has become virtually the sole basis of schistosomiasis control in sub-Saharan Africa and elsewhere, and the drug is reviewed here in the context of the increasing rate that it is being used for this purpose.
Journal ArticleDOI
Praziquantel for the treatment of schistosomiasis: its use for control in areas with endemic disease and prospects for drug resistance.
TL;DR: While resistance may not pose an obvious or immediate threat to the usefulness of praziquantel, complacency and a failure to monitor developments may have serious consequences in the longer term since it will be the only drug that is readily available for large-scale treatment of schistosomiasis.